Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $80.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on CLDX. Cantor Fitzgerald restated an overweight rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. Stifel Nicolaus started coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They set a buy rating and a $58.00 price objective on the stock. Finally, Wolfe Research started coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an outperform rating and a $51.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $62.17.

Celldex Therapeutics Trading Down 7.4 %

Shares of NASDAQ:CLDX opened at $34.78 on Tuesday. The stock’s fifty day simple moving average is $36.74 and its two-hundred day simple moving average is $39.10. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18. The stock has a market cap of $2.29 billion, a PE ratio of -12.20 and a beta of 1.58.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.11. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. On average, sell-side analysts forecast that Celldex Therapeutics will post -2.39 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Elizabeth Crowley sold 15,000 shares of Celldex Therapeutics stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $35.06, for a total value of $525,900.00. Following the completion of the sale, the vice president now owns 9,074 shares of the company’s stock, valued at approximately $318,134.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Samuel Bates Martin sold 35,000 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the sale, the chief financial officer now owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Elizabeth Crowley sold 15,000 shares of Celldex Therapeutics stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $35.06, for a total value of $525,900.00. Following the completion of the sale, the vice president now directly owns 9,074 shares of the company’s stock, valued at approximately $318,134.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 266,332 shares of company stock valued at $9,155,821. 3.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in Celldex Therapeutics by 48.9% during the 4th quarter. BNP Paribas Financial Markets now owns 136,601 shares of the biopharmaceutical company’s stock valued at $5,418,000 after buying an additional 44,878 shares in the last quarter. Vanguard Group Inc. grew its holdings in Celldex Therapeutics by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after buying an additional 427,827 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Celldex Therapeutics by 105.3% during the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after buying an additional 1,413,722 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after buying an additional 47,844 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its holdings in Celldex Therapeutics by 166.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $15,864,000 after buying an additional 250,000 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.